Silence Therapeutics (SLN) Common Equity (2019 - 2025)
Historic Common Equity for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $74.1 million.
- Silence Therapeutics' Common Equity fell 4154.27% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 4154.27%. This contributed to the annual value of $134.0 million for FY2024, which is 50938.94% up from last year.
- Latest data reveals that Silence Therapeutics reported Common Equity of $74.1 million as of Q3 2025, which was down 4154.27% from $94.2 million recorded in Q2 2025.
- Silence Therapeutics' Common Equity's 5-year high stood at $156.8 million during Q1 2024, with a 5-year trough of $5.4 million in Q1 2022.
- Over the past 5 years, Silence Therapeutics' median Common Equity value was $21.4 million (recorded in 2023), while the average stood at $47.7 million.
- As far as peak fluctuations go, Silence Therapeutics' Common Equity crashed by 8290.33% in 2022, and later soared by 171727.97% in 2024.
- Quarter analysis of 5 years shows Silence Therapeutics' Common Equity stood at $11.5 million in 2021, then soared by 125.26% to $25.9 million in 2022, then plummeted by 71.51% to $7.4 million in 2023, then soared by 1717.28% to $134.0 million in 2024, then plummeted by 44.74% to $74.1 million in 2025.
- Its Common Equity stands at $74.1 million for Q3 2025, versus $94.2 million for Q2 2025 and $112.7 million for Q1 2025.